Agency for Healthcare Research and Quality (2012) AHRQ Health Literacy Universal Precautions Toolkit (2nd edn). AHRQ.
American Psychiatric Association (2006) American Psychiatric Association Practice Guidelines for the Treatment of Psychiatric Disorders: Compendium. APA.
Barrowclough, C, Haddock, G, Tarrier, N, et al. (2001) Randomized controlled trial of motivational interviewing, cognitive behavior therapy, and family intervention for patients with comorbid schizophrenia and substance use disorders. American Journal of Psychiatry, 158: 1706–13.
Birley, J, Brown, GW (1970) Crises and life changes preceding the onset or relapse of acute schizophrenia: clinical aspects. British Journal of Psychiatry, 116: 327–33.
Boss, GR, Seegmiller, JE (1981) Age-related physiological changes and their clinical significance. Western Journal of Medicine, 135: 434–40.
Calarge, CA, Nicol, G, Schlecte, JA, et al. (2014) Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. Journal of Child and Adolescent Psychopharmacology, 24: 120–9.
Chemerinski, E, Ho, BC, Flaum, M, et al. (2002) Insomnia as a predictor for symptom worsening following antipsychotic withdrawal in schizophrenia. Comprehensive Psychiatry, 43: 393–6.
Chouinard, G (1991) Severe cases of neuroleptic-induced supersensitivity psychosis: diagnostic criteria for the disorder and its treatment. Schizophrenia Research, 5: 21–33.
Copeland, ME (1997) Wellness Recovery Action Plan. Peach Press.
Davidson, L, Tondora, J, Miller, R, et al. (2015) Person-centered care. In Person-Centered Care for Mental Illness: The Evolution of Adherence and Self-Determination (ed Corrigan, P). American Psychological Association.
Davidson, L, Tondora, J, Pavlo, AJ, et al. (2017) Shared decision making within the context of recovery-oriented care. Mental Health Review Journal, 22: 179–190.
de Kuijper, G, Mulder, H, Evenhuis, H, et al. (2013) Effects of controlled discontinuation of long-term used antipsychotics on weight and metabolic parameters in individuals with intellectual disability. Journal of Clinical Psychopharmacology, 33: 520–4.
Deegan, PE (1993) Recovering our sense of value after being labeled: mentally ill. Journal of Psychosocial Nursing and Mental Health Services, 31: 7–9.
Deegan, PE, Drake, RE (2006) Shared decision making and medication management in the recovery process. Psychiatric Services, 57: 1636–9.
Dixon, L, Perkins, D, Calmes, C (2009) Guideline watch (September 2009): practice guideline for the treatment of patients with schizophrenia. Arlington, VA: American Psychiatric Association.
Drake, RE, O'Neal, EL, Wallach, MA (2008) A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. Journal of Substance Abuse Treatment, 34: 123–38.
Essock, SM, Covell, NH, Leckman-Westin, E, et al. (2009) Identifying clinically questionable psychotropic prescribing practices for Medicaid recipients in New York State. Psychiatric Services, 60: 1595–602.
Farkas, MD, Anthony, WA, Cohen, MR (1989) An overview of psychiatric rehabilitation: the approach and its programs. In Psychiatric Rehabilitation Programs: Putting Theory into Practice (eds Farkas, MD, Anthony, WA): 1–27. Johns Hopkins University Press.
Galling, B, Roldan, A, Hagi, K (2017) Antipsychotic augmentation vs. monotherapy in schizophrenia: systematic review, meta-analysis and meta-regression analysis. World Psychiatry, 16: 77–89.
Ganguly, R, Kotzan, JA, Miller, LS, et al. (2004) Prevalence, trends, and factors associated with antipsychotic polypharmacy among Medicaid-eligible schizophrenia patients, 1998-2000. Journal of Clinical Psychiatry, 65: 1377–88.
Gilbert, PL, Harris, MJ, MacAdams, LA, et al. (1995) Neuroleptic withdrawal in schizophrenic patients: a review of the literature. Archives of General Psychiatry, 52: 173–88.
Glazer, WM, Morgenstern, H, Schooler, N, et al. (1990) Predictors of improvement in tardive dyskinesia following discontinuation of neuroleptic medication. British Journal of Psychiatry, 157: 585–92.
Goff, DC, Falkai, P, Fleischhacker, WW, et al. (2017) The long-term effects of antipsychotic medication on clinical course in schizophrenia. American Journal of Psychiatry, 174: 840–9.
Gupta, S, Cahill, JD (2016) A prescription for “deprescribing” in psychiatry. Psychiatric Services, 67: 904–7.
Harrow, M, Jobe, TH (2013) Does long-term treatment of schizophrenia with antipsychotic medications facilitate recovery? Schizophrenia Bulletin, 39: 962–5.
Hayes, SC, Strosahl, KD, Wilson, KG (1999) Acceptance and commitment therapy: An experiential approach to behavior change. New York: Guilford.
Jacobson, L, Greeley, D (2001) What is recovery? A conceptual model and explication. Psychiatric Services, 52: 482–5.
Lehman, AF, Steinwachs, DM (1998) Translating research into practice: the Schizophrenia Patient Outcomes Research Team (PORT) treatment recommendations. Schizophrenia Bulletin, 24: 1–10.
Lehman, AF, Lieberman, JA, Dixon, LB, et al. (2004) Practice guideline for the treatment of partients with schizophrenia. American Journal of Psychiatry, 161(2 SUPPL): 1–56.
Leucht, S, Tardy, M, Komossa, K, et al. (2012) Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis. Lancet, 379: 2063–71.
McFarlane, WR, Dixon, L, Lukens, E, et al. (2003) Family psychoeducation and schizophrenia: a review of the literature. Journal of Marital and Family Therapy, 29: 223–45.
McGurk, SR, Twamley, EW, Sitzer, DI, et al. (2007) A meta-analysis of cognitive remediation in schizophrenia. American Journal of Psychiatry, 164: 1791–802.
Moncrieff, J (2006) Does antipsychotic withdrawal provoke psychosis? Review of the literature on rapid onset psychosis (supersensitivity psychosis) and withdrawal-related relapse. Acta Psychiatrica Scandinavica, 114: 3–13.
Petrakis, IL, Nich, C, Ralevski, E (2006) Psychotic spectrum disorders and alcohol abuse: a review of pharmacotherapeutic strategies and a report on the effectiveness of naltrexone and disulfiram. Schizophrenia Bulletin, 32: 644–54.
Pilling, S, Bebbington, P, Kuijpers, E, et al. (2002) Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychological Medicine, 32, 763–82.
Reeve, E, Wiese, MD (2014a) Benefits of deprescribing on patients’ adherence to medications. International Journal of Clinical Pharmacy, 36: 26–9.
Reeve, E, Shakib, S, Hendrix, I (2014b) Review of deprescribing processes and development of an evidence-based, patient-centred deprescribing process. British Journal of Clinical Pharmacology, 78: 738–47.
Reeve, E, Denig, P, Hilmer, SN (2016) The ethics of deprescribing in older adults. Journal of Bioethical Inquiry, 13: 1–10.
Rossello, X, Pocock, SJ, Julian, DG (2015) Long-term use of cardiovascular drugs: challenges for research and for patient care. Journal of the American College of Cardiology, 66: 1273–85.
Saha, S, Chant, D, McGrath, J (2007) A systematic review of mortality in schizophrenia: is the differential mortality gap worsening over time? Archives of General Psychiatry, 64: 1123–31.
Sánchez-Ortuño, MM, Edinger, JD (2012) Cognitive-behavioral therapy for the management of insomnia comorbid with mental disorders. Current Psychiatry Reports, 14: 519–28.
Schooler, NR (1993) Reducing dosage in maintenance treatments of schizophrenia: review and prognosis. British Journal of Psychiatry, 163(suppl 22): 58–65.
Schooler, NR (2004) Maintenance medication for schizophrenia: strategies for dose reduction. Focus, 2: 175–86.
Scott, IA, Hilmer, SN, Reeve, E, et al. (2015) Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Internal Medicine, 175: 827–34.
Sendt, KV, Tracy, DK, Bhattacharya, S (2015) A systematic review of factors influencing adherence to antipsychotic medication in schizophrenia-spectrum disorders. Psychiatry Research, 225: 14–30.
Stahl, S, Grady, M (2004) A critical review of atypical antipsychotic utilization: comparing monotherapy with polypharmacy and augmentation. Current Medicinal Chemistry, 11: 313–27.
Stanhope, V, Ingoglia, C, Schmelter, B, et al. (2013) Impact of person-centered planning and collaborative documentation on treatment adherence. Psychiatric Services, 64: 76–9.
Swofford, CD, Kasckow, JW, Scheller-Gilkey, G, et al. (1996) Substance use: a powerful predictor of relapse in schizophrenia. Schizophrenia Research, 20: 145–51.
Takeuchi, H, Kantor, N, Uchida, H, et al. (2017) Immediate vs gradual discontinuation in antipsychotic switching: a systematic review and meta-analysis. Schizophrenia Bulletin, 43: 862–71.
Taylor, D, Paton, C, Kapur, S (2015) The Maudsley Prescribing Guidelines in Psychiatry (12th edn). Wiley Blackwell.
Tondora, J, Miller, R, Slade, M, et al. (2014) Partnering for Recovery in Mental Health: A Practical Guide to Person-Centered Planning. Wiley Blackwell.
Viguera, AC, Baldessarini, RJ, Hegarty, JD, et al. (1997) Clinical risk following abrupt and gradual withdrawal of maintenance neuroleptic treatment. Archives of General Psychiatry, 54: 49–55.
Woodward, MC (2003) Deprescribing: achieving better health outcomes for older people through reducing medications. Journal of Pharmacy Practice and Research, 33: 323–8.
Wunderink, L, Neinhuis, FJ, Sytema, S, et al. (2007) Guided discontinuation versus maintenance treatment in remitted first-episode psychosis: relapse rates and functional outcome. Journal of Clinical Psychiatry, 68: 654–61.
Wunderink, L, Nieboer, RM, Wiersma, D, et al. (2013) Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry, 70: 913–20.
Zipursky, RB, Menezes, NM, Streiner, DL (2014) Risk of symptom recurrence with medication discontinuation in first-episode psychosis: a systematic review. Schizophrenia Research, 152: 408–14.